Abstract
Doris Pischedda, Giuseppe Pontillo, Giuseppe De Simone, Sirio Cocozza, Filip Cipranic, Anita Monteverdi, Claudia A. M. Gandini Wheeler‐Kingshott, Fulvia Palesi, Egidio Ugo D'Angelo
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Schizophrenia-An Overview
10.1001/jamapsychiatry.2019.3360 · 2020
10.1007/978-0-387-78665-0_87
10.1007/978-0-387-78665-0_87
The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics
10.1002/wps.20959 · 2022
: The Lived Experiences of Family Members and Carers of People with Psychosis: A Bottom-Up Review Co-Written by Experts by Experience and Academics
10.1159/000528513 · 2023
10.1038/s41380-023-02138-4
10.1038/s41380-023-02138-4
: Suicide in Schizophrenia: An Educational Overview
10.3390/medicina55070361 · 2019
What is schizophrenia – symptomatology
10.1017/s1092852924000622 · 2025
10.1093/schbul/sbp006
10.1093/schbul/sbp006
10.1016/j.biopsych.2022.06.017
10.1016/j.biopsych.2022.06.017
10.1038/s41582-023-00904-0
10.1038/s41582-023-00904-0
10.3389/fncel.2024.1386583
10.3389/fncel.2024.1386583
10.1016/bs.apha.2016.01.006
10.1016/bs.apha.2016.01.006
10.1093/schbul/sbs076
10.1093/schbul/sbs076
10.1523/jneurosci.4650-03.2004
10.1523/jneurosci.4650-03.2004
10.1016/j.tins.2014.12.005
10.1016/j.tins.2014.12.005
10.1016/j.neuron.2013.02.011
10.1016/j.neuron.2013.02.011
In vivo assessment of GABAergic inhibition and glutamate facilitation in treatment-resistant schizophrenia: a TMS study integrating clinical, cognitive, and neurophysiological evaluations
10.1038/s41537-025-00634-w · 2025
: Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients
10.1016/j.pnpbp.2021.110493 · 2022
Machine Learning algorithm unveils glutamatergic alterations in the post-mortem schizophrenia brain
10.1038/s41537-022-00231-1 · 2022
10.1016/j.biopsych.2015.08.025
10.1016/j.biopsych.2015.08.025
Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia
10.1001/jamapsychiatry.2015.2680 · 2016
: Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment
10.1146/annurev-pharmtox-051921-093250 · 2023
Hippocampal circuit dysfunction in psychosis
2022
10.1038/s41380-023-01949-9
10.1038/s41380-023-01949-9
10.1017/s1092852914000601
10.1017/s1092852914000601
10.1093/schbul/sbu170
10.1093/schbul/sbu170
: CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics
10.1192/bjo.2024.230 · 2024
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
10.1016/s2215-0366(20)30513-7 · 2021
Unresolved referenced work
Kept as external metadata until matched
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
10.1007/s40261-024-01377-9 · 2024
10.1038/s41380-026-03543-1
10.1038/s41380-026-03543-1
: A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy)
10.1080/01612840.2024.2427561 · 2024
10.1152/jn.00338.2011
10.1152/jn.00338.2011
10.1093/schbul/sbx034
10.1093/schbul/sbx034
10.1093/schbul/sbad022
10.1093/schbul/sbad022
Early life stress, low-grade systemic inflammation and weaker suppression of the default mode network (DMN) during face processing in Schizophrenia
10.1038/s41398-023-02512-4 · 2023
10.1093/schbul/sby094
10.1093/schbul/sby094
: Posterior Cerebellar Resting-State Functional Hypoconnectivity: A Neural Marker of Schizophrenia Across Different Stages of Treatment Response
10.1016/j.biopsych.2024.01.027 · 2024
10.1101/2024.10.25.620271
10.1101/2024.10.25.620271
10.3389/fpsyt.2024.1474313
10.3389/fpsyt.2024.1474313
Glutamatergic dysfunction in Schizophrenia
10.1038/s41398-022-02253-w · doi-reference
10.1038/aps.2017.172
10.1038/aps.2017.172 · doi-reference
10.1016/j.schres.2014.12.026
10.1016/j.schres.2014.12.026 · doi-reference
Disrupted default mode network connectivity and its role in negative symptoms of schizophrenia
10.1016/j.psychres.2025.116489 · doi-reference
10.1016/j.eurpsy.2015.01.002
10.1016/j.eurpsy.2015.01.002 · doi-reference
Consistent frontal-limbic-occipital connections in distinguishing treatment-resistant and non-treatment-resistant schizophrenia
10.1016/j.nicl.2024.103726 · doi-reference
: Reduced intrinsic visual cortical connectivity is associated with impaired perceptual closure in schizophrenia
10.1016/j.nicl.2017.04.012 · doi-reference
10.3389/fpsyt.2025.1566184
10.3389/fpsyt.2025.1566184 · doi-reference
10.18999/nagjms.80.3.317
10.18999/nagjms.80.3.317 · doi-reference
Alterations of the occipital lobe in schizophrenia
10.17712/nsj.2015.3.20140757 · doi-reference
10.1001/archpsyc.62.5.495
10.1001/archpsyc.62.5.495 · doi-reference
10.1016/j.psychres.2020.112957
10.1016/j.psychres.2020.112957 · doi-reference
: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
10.1111/j.2517-6161.1995.tb02031.x · doi-reference
: Regression Shrinkage and Selection Via the Lasso
10.1111/j.2517-6161.1996.tb02080.x · doi-reference
10.2307/2280779
10.2307/2280779 · doi-reference
X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. The London
10.1080/14786440009463897 · doi-reference
10.2307/3001968
10.2307/3001968 · doi-reference
10.1093/biomet/6.1.1
10.1093/biomet/6.1.1 · doi-reference
10.1016/j.neuroimage.2022.118973
10.1016/j.neuroimage.2022.118973 · doi-reference
10.1152/jn.00339.2011
10.1152/jn.00339.2011 · doi-reference
10.1016/j.neuroimage.2014.11.001
10.1016/j.neuroimage.2014.11.001 · doi-reference
10.1016/j.neuroimage.2019.116137
10.1016/j.neuroimage.2019.116137 · doi-reference
10.3389/fncel.2020.00240
10.3389/fncel.2020.00240 · doi-reference
10.1016/j.neuroimage.2012.06.005
10.1016/j.neuroimage.2012.06.005 · doi-reference
10.1016/j.neuroimage.2006.05.056
10.1016/j.neuroimage.2006.05.056 · doi-reference
10.1016/j.neuroimage.2011.02.046
10.1016/j.neuroimage.2011.02.046 · doi-reference
10.1006/nimg.2001.0978
10.1006/nimg.2001.0978 · doi-reference
10.1016/j.neuroimage.2007.04.042
10.1016/j.neuroimage.2007.04.042 · doi-reference
10.1016/j.neuroimage.2011.06.080
10.1016/j.neuroimage.2011.06.080 · doi-reference
10.1016/s1361-8415(02)00054-3
10.1016/s1361-8415(02)00054-3 · doi-reference
10.1002/ima.22005
10.1002/ima.22005 · doi-reference
10.1016/j.neuroimage.2011.09.015
10.1016/j.neuroimage.2011.09.015 · doi-reference
10.1176/appi.ajp.2009.09060802
10.1176/appi.ajp.2009.09060802 · doi-reference
Diazepam modulates anterior cingulate glutamate levels in people at clinical high-risk for psychosis
10.1093/ijnp/pyaf078 · doi-reference
10.3389/fnagi.2023.1204134
10.3389/fnagi.2023.1204134 · doi-reference
10.3389/fnagi.2022.868342
10.3389/fnagi.2022.868342 · doi-reference
10.1523/jneurosci.5068-13.2014
10.1523/jneurosci.5068-13.2014 · doi-reference
10.64898/2026.05.06.26352533
10.64898/2026.05.06.26352533 · doi-reference
10.1016/j.tins.2022.06.007
10.1016/j.tins.2022.06.007 · doi-reference
10.1177/02698811251319458
10.1177/02698811251319458 · doi-reference